ArticlePDF Available

Metadichol ® A Novel Nano Lipid; GPR 120 Agonist International Journal of Diabetes & its Complications

Authors:

Abstract and Figures

Metadichol® is a Nanoemulsion of long-chain alcohols found in many foods. Metadichol acts as an inverse ag-onist on Nuclear Vitamin D receptors (VDR) that have a ubiquitous presence in cells and acts by modulating the immune system and affects many biological processes to modulate many diseases. We have demonstrated that Metadichol is useful in both type 1 and two diabetes and in modulating insulin levels and reducing sugar levels and thus increasing insulin sensitivity. We had earlier shown that it binds to VDR and thus an effect on glucose homeostasis that is a hallmark of VDR pathways. We now report also that it is an agonist of GPR120 (G protein-coupled receptor 120) which has emerged as a key target for metabolic diseases like obesity and insulin resistance. In the in-vitro assay, Metadichol is comparable to GW9508 the most extensively used standard compound in GPR 120 research.
No caption available
… 
Content may be subject to copyright.
Volume 1 | Issue 1 | 1 of 4
Int J Diabetes Complications, 2017
Metadichol ® A Novel Nano Lipid; GPR 120 Agonist
Research Article
Nanorx Inc, PO Box 131, Chappaqua, NY 10514, US
*Correspondance:
PR Raghavan, Founder and CEO, Nanorx Inc, Chappaqua, NY,
USA, Tel: (914) 671-0224; E-mail: raghavan@nanorxinc.com.
Received: 15 Apr 2017; Accepted: 02 May 2017
Raghavan P.R
International Journal of Diabetes & its Complications
ABSTRACT
Metadichol® is a Nanoemulsion of long-chain alcohols found in many foods. Metadichol acts as an inverse ag-
onist on Nuclear Vitamin D receptors (VDR) that have a ubiquitous presence in cells and acts by modulating the
immune system and affects many biological processes to modulate many diseases.
We have demonstrated that Metadichol is useful in both type 1 and two diabetes and in modulating insulin levels
and reducing sugar levels and thus increasing insulin sensitivity. We had earlier shown that it binds to VDR and
thus an effect on glucose homeostasis that is a hallmark of VDR pathways. We now report also that it is an
agonist of GPR120 (G protein-coupled receptor 120) which has emerged as a key target for metabolic diseases
like obesity and insulin resistance.
In the in-vitro assay, Metadichol is comparable to GW9508 the most extensively used standard compound in GPR
120 research.
Research Article
Citation: Raghavan P.R. Metadichol® A Novel Nano Lipid; GPR 120 Agonist. Int J Diabetes Complications. 2017; 1-3.
Keywords
Metadichol, VDR, Nuclear receptors, Inverse agonists, Protean
agonists, GPR 120, FFAR4, Lipids, Insulin Resistance, Insulin
sensitivity, Type 1 and Type 2 diabetes, Network biology, Multiple
receptors targeting, BCAT1, PPARG.
Introduction
Diabetes is rampant across the world and was the cause of 4.6
million deaths in 2011. By the year 2030, over 450 million people
will be affected [1].
Lifestyle disease modication like diet control can help in
preventing Type two diabetes. Many experimental drugs are in
various phases of development, but despite new insights into the
mechanism of the disease, as of today, no effective solution is in
sight.
Increasingly research has been that focussed on the superfamily
of GPCRs and there are over 800, seven-transmembrane receptors
that display different physiological and pathological functions [2].
Free fatty acids (FFAs) are known to act in regulating physiological
functions through G-protein-coupled receptors the most important
being GPR-120, also known as FFAR4, which is now an important
therapeutic target against diabetes [3].
GPR120 have a ubiquitous presence in various tissues and cells
[4]. GPR120 has functions in the homeostatic regulation of
systemic metabolism and inammation depending on this different
tissue distribution. GPR120 activation can lead to positive effects
on type 2 diabetes. GPR120 signals via both β- arrestin 2 and G
proteins in the reported studies. GPR120 is an emerging target in
the eld of metabolic diseases.
Experimental
The GPCR assay was carried out by DiscoverRX, CA USA
using PathHunter® assays which use adapted β-galactosidase
complementation system. Enzyme Fragment Complementation
(EFC) with β-galactosidase (β-Gal) as the functional reporter. In
the PathHunter® β-Arrestin assay. The GPCR assays are the whole
cell, functional tests that directly measure activity by detecting the
interaction of β-Arrestin with the activated GPCR. It monitors the
activation of a GPCR in a homogenous, non-imaging assay format.
The enzyme is split into two inactive complementary portions: a
small peptide called ProLink™ (PK) and a larger protein, called
Enzyme Acceptor (EA). PK and EA are then expressed as fusion
proteins in the cell, with PK fused to the GPCR of in-terest, and
Volume 1 | Issue 1 | 2 of 4Int J Diabetes Complications, 2017
EA fused to β-Arrestin. When the target GPCR is activated, and
β-Arrestin recruited to the receptor, PK, and EA complementation
occurs, restoring β-Galactosidase activity which is measured using
chemilumi-nescent PathHunter® Detection Reagents. GW9508, a
known GPR 120 agonist, was used as the standard.
Cell Handling
PathHunter® cell lines were thawed from freezer stocks
according to standard procedures.
Cells were seeded in a total volume of 20 μL into white-
walled, 384-well microplates and incubated at 37°C for a
stipulated time before testing.
Agonist Format
For agonist determination, cells were incubated with the
sample to induce the response.
Intermediate dilution of samples was carried out to obtain the
5X samples required in assay buffer
ve μL of 5X sample was added to cells and incubated at 37°C
or room temperature for 90 or 180 minutes. Fi-nal test vehicle
concentration was 1%.
Signal Detection
Assay signal generated through a single addition of 12.5 or 15
μL (50% v/v) of PathHunter agent for detection followed by
one-hour incubation at room temperature.
Microplates were then read following signal generation with a
Perkin Elmer EnvisionTM instrument for chemi-luminescent
signal detection.
Data Analysis
Compound activity was analyzed using CBIS data analysis
suite (ChemInnovation, CA).
For agonist mode assays, percentage activity was calculated
using as follows;
% Activity =100% x (mean RLU of test sample — mean RLU of
vehicle control) / (mean MAX control ligand — mean RLU of
vehicle control).
Agonist assays, data was normalized to the maximal and minimal
response observed in the presence of control ligand and vehicle.
Summary of Results
Table 1 shows the summary of results. Table 2 and 2-1 show the
raw data, and Figure 1 shows the graphs of the agonist activity.
Metadichol has the same response as the known GPR120 agonist
GW9508.
Table 1
Compound
Name
Assay
Name
Assay
Format
Assay
Target
EC50 (ug/
mL)
Slope
Curve
Bottom
Curve Top
Max
Response
Metadichol Arrestin Agonist GPR120 3.3141 1.48 -4.1 105 105.3
GW9508 Arrestin Agonist GPR120 3.478 1.03 -5.5 105 101.68
Table 2
Metadichol
Well ID Concentration Raw Value Percent Efcacy
E21 0.048828 16800 -6.3995
E22 0.048828 16000 -8.468
E19 0.097656 17000 -5.8824
E20 0.097656 17600 -4.331
E17 0.19531 16800 -6.3995
E18 0.19531 17000 -5.8824
E15 0.39063 21000 4.4602
E16 0.39063 19000 -0.71105
E13 0.78125 23000 9.6315
E14 0.78125 22800 9.1144
E11 1.5625 29800 27.214
E12 1.5625 27600 21.526
E9 3.125 38200 48.933
E10 3.125 36800 45.314
E7 6.25 48000 74.273
E8 6.25 45000 66.516
E5 12.5 56200 95.475
E6 12.5 55400 93.407
E3 25 62000 110.47
E4 25 58000 100.13
GW6506
Well ID Concentration Raw Value Percent Efcacy
A21 0.0050805 16200 -7.9509
A22 0.0050805 18400 -2.2624
A19 0.015242 16000 -8.468
A20 0.015242 16600 -6.9166
A17 0.045725 17000 -5.8824
A18 0.045725 18800 -1.2282
A15 0.13717 18800 -1.2282
A16 0.13717 18200 -2.7796
A13 0.41152 22600 8.5973
A14 0.41152 21200 4.9774
A11 1.2346 27400 21.008
A12 1.2346 27800 22.043
A9 3.7037 40800 55.656
A10 3.7037 39000 51.002
A7 11.111 49400 77.893
A8 11.111 48000 74.273
A5 33.333 55600 93.924
A6 33.333 59000 102.71
A3 100 61000 107.89
A4 100 56200 95.475
Discussion
Metadichol ® is a Nanoemulsion in water and has a particle size of
less than 60 nm. Its mechanism of action is through its binding to
the vitamin D receptor (VDR) as an inverse agonist [5].
The natural ligand for the VDR is 1,25-Dihydroxy Vitamin D is
and acts as an agonist. Metadichol can act as both positive or as
Volume 1 | Issue 1 | 3 of 4Int J Diabetes Complications, 2017
negative agonists on the same receptor a property characteristic
of protean agonist [6,7]. In the absence of constitutive activity,
it behaves as an active agonist. If constitutive activity is present,
it acts as an inverse agonist. Metadichol can reduce or increase
insulin secretion [5,8].
For the functioning of the skeletal system [9], Vitamin D is very
critical for the regulation of the immune system [9]. It has a vital
role not only in controlling insulin synthesis and secretion as well
[10,11]. Metadichol in addi-tion to binding with VDR also binds to
other nuclear receptors that include PPAR Gamma [12].
Flawed metabolism of Branched Chain Amino Acid (BCAA) is
associated with many chronic conditions like type II diabetes and
other childhood disorders [13]. Metformin has been shown to in-
hibit expression of mitochondrial branched-chain aminotransfer-
ase (BCAT) [14]. We have recently shown that Metadichol is a
potent inhibitor of BCAT1 [15].
The Agonism exhibited by Metadichol in GPR 120 assays show
that it is acting on more than one target, VDR, BCAT1, has been
shown previously. The current research approach that of a lock
(receptor) and key (drug). The search to mitigate the side effects
of drugs by looking for high selective ligands and has proven to
be cost and time consuming without any in many ways a failure.
Useful drugs act via pathways in targeting multiple proteins
rather than single targets. Protein kinase inhibitors like Sutent and
Gleevec, have demonstrated that their anticancer actions are due to
their effects on multiple kinases [16].
Yıldırım, M.A, et.al suggest that there are many keys open a lock
but the goal of drug discovery is to have a single key to open many
locks, i.e., act via multiple pathways [17]. A practical approach
for mitigating disease states may require multiple activities to be
efcacious, together with the observation that perturbs biological
networks is more important than individual targets [18].
Previously we have published case studies of Metadichol ® in
Type 1 diabetes and type 2 diabetes patients [8,19]. It appears
to be more efcient than many drugs on the market as it works
multiple pathways on multiple receptor targets. Metadichol acts
at the nuclear receptor level (VDR) and the transmembrane level
(GPR120) and the Cytoplasm and mitochondrial level (inhibition
of BCAT1) is probably what makes it such a powerful treatment of
choice in diabetes relate diseases.
Conclusion
Metadichol has the potential to serve in mitigating diabetes
with a broad spectrum of activity and with a safety with no
toxicity at doses of up to 5000 mg/kg [20-22]. Metadichol is a
a far effective substitute to prescription drugs, which have been
largely ineffective in diabetes and have many side effects that add
to health care costs.
References
1. Zimmet P, Alberti KG, Shaw J. Global and societal implications
of the diabetes epidemic. Nature Dec. 2001; (6865): 782-787.
2. Tang XL. Orphan G protein-coupled receptors (GPCRs):
biological functions and potential drug targets. Acta Pharmacol
Sin. 2012; 33: 363-371.
3. Cornall LM. GPR120 agonist as the countermeasure against
metabolic diseases. Drug Discov Today. 2013; 19: 670-679.
4. Oh DY. GPR120 is an omega-3 fatty acid receptor mediating
potent anti-inammatory and insulin-sensitizing effects. Cell.
2010; 42: 687-698.
5. P.R. Raghavan. US patents, 8,722,093 (2014) and 9,006,292.
2015.
6. Terry Kenakin. Functional Selectivity through Protean and
Biased Agonism: Who Steers the Ship? Mol Phar-macol.
2007; 72: 1393-1402.
7. Neubig RR. Missing Links, Mechanisms of Protean Agonism,
Mol Pharmacol. 2000; l71: 200-1202.
8. P.R. Raghavan. A case report of Type 1 Diabetes. Journal of
the Science of Healing Outcomes. 2010; 2: 8-9.
9. Christakos S, Hewison M, Gardner DG, et al. Vitamin D:
Beyond Bone. Ann N Y Acad Sci. 2013; 1287: 45-58.
Volume 1 | Issue 1 | 4 of 4Int J Diabetes Complications, 2017
© 2017 Raghavan P.R. is article is distributed under the terms of the Creative Commons Attribution 4.0 International License
10. Bikle DD. Vitamin D and immune function: Understanding
common pathways. Curr Osteo-poros Rep 2009; 7: 58-63.
11. Palmer X, González-Clemente JM, Blanco-Vaca F, et al. Role
of vitamin D in the pathogene-sis of type 2 diabetes mellitus.
Diabetes Obes Metab. 2008; 10: 185-197.
12. Raghavan PR. Unpublished work.
13. Skvorak KJ. Animal models of maple syrup urine disease. J
Inherit Metab Dis. 2009; 32: 229-246.
14. Davis S. Sonnet. Metformin inhibits Branched Chain Amino
Acid (BCAA) derived ketoaci-dosis and promotes metabolic
homeostasis in MSUD. Nature Scientic Reports. 2006; 6:
28775.
15. P.R. Raghavan, 2017; Improving Longevity with Metadichol
® by inhibiting Bcat-1 Gene. Journal of Aging Science. 5:1,
DOI: 10.4172/2329-8847.1000174
16. Roth BL, Shefer DJ, Kroeze WK, et al. Nat Rev Drug
Discov. 2004; 3: 353-359.
17. Yildırım MA. Drug-target network. Nat Biotechnol. 2007; 25:
1119-1126.
18. Andrew Hopkins. Network pharmacology: the next paradigm
in drug discovery. Nature Chemical Biology. 2007; 4: 11.
19. PR Raghavan. Metadichol and Type 2 Diabetes A case report.
Journal of the Science of Healing Outcomes: 2016; 32: 5-10.
20. Alemán CL, Más R, Hernández, et al. A 12-month study of
policosanol oral toxicity in Spra-gue Dawley rats. Toxicol
Lett. 1994; 70: 77-87.
21. Alemán, CL, Más Ferreiro. Carcinogenicity of policosanol in
Sprague-Dawley rats: A 24-month study. Teratog Carcinog
Mutagen. 1994; 14: 239-249.
22. Aleman, CL, Puig MN, EIN, EC, et al. Carcinogenicity of
policosanol in mice: An 18-month study. 1995.
... Vitamin D3 role in innate immunity is to enable keratinocytes to recognize and respond to bacteria and to protect wounds against infection [31] Metadichol as we documented earlier has a powerful effect on diabetic patients [32,33]. Metadichol is an agonist of GPR 120 [34]. This is another pathway though which it can act as shown by Arantes El et al. [35] that the topical use of GPR 120 agonists like polyunsaturated fatty acids (PUFAs) can accelerate skin wound healing. ...
Article
Full-text available
Metadichol ® is a nano formulation of long-chain lipid alcohols derived from food It is a inverse agonist of Vitamin D receptor (VDR), Aryl hydrocarbon receptor (AHR), and ROR gamma (RORC) that could have beneficial effects on skin diseases. We now present case studies of patients with various skin diseases who has symptoms mitigated on treatment with Metadichol. The proposed mechanism is that Metadichol by its actions on the above mentioned nuclear receptors affects Th1, TH2,Th 17, IL 17 and IL22 and IL 23 pathways that exacerbate many Skin diseases. Metadichol is the first molecule to successfully navigate around the problems involved with promiscuous ligands and targets. It fulfills the goals of the emerging field of Polypharmacology i.e a single drug is able to bind to multiple targets beyond the "one drug, one target" concept. We show how Metadichol is an innovative treatment for treating multiple skin diseases like eczema, acne, diabetic wounds viral and bacterial infection and also improving skin texture. Metadichol ® is a safe non toxic low cost solution and is an alternative to numerous clinical candidates in combating over 3000 skin diseases.
Article
Full-text available
Metadichol ® [1] is a Nanoemulsion of long-chain alcohols found in many foods. It is commonly called Policosanol and is present in foods such as rice, sugar cane, wheat, peanuts Metadichol acts as an inverse agonist on Nuclear Vitamin D receptors (VDR) that are present in cells throughout the body to stimulate the immune system and affects many biologIcal processes to modulate many diseases. Branched-chain amino acid transferase (BCAT1) catalyzes the reversible transamination of leucine, isoleucine, and valine branched-chain amino acids (BCAA) to their respective alpha-keto acids, liberating L-glutamate. When this gene is inhibited, the amino acid chains accumulated in the tissue triggering longevity in the nematodes. The health and longevity of the nematodes improved when BCAT1 was inhibited. Gabapentin has been shown to inhibit BCAT1, but IC50 is 10000 uM. Metadichol® inhibits BCAT1 with an IC50 of 3.3 um, 3000 times more potent than Gabapentin.
Article
Full-text available
Maple Syrup Urine Disease (MSUD) is an inherited disorder caused by the dysfunction in the branched chain keto-acid dehydrogenase (BCKDH) enzyme. This leads to buildup of branched-chain keto-acids (BCKA) and branched-chain amino acids (BCAA) in body fluids (e.g. keto-isocaproic acid from the BCAA leucine), leading to numerous clinical features including a less understood skeletal muscle dysfunction in patients. KIC is an inhibitor of mitochondrial function at disease relevant concentrations. A murine model of intermediate MSUD (iMSUD) shows significant skeletal muscle dysfunction as by judged decreased muscle fiber diameter. MSUD is an orphan disease with a need for novel drug interventions. Here using a 96-well plate (liquid chromatography- mass spectrometry (LC-MS) based drug-screening platform we show that Metformin, a widely used anti-diabetic drug, reduces levels of KIC in patient-derived fibroblasts by 20–50%. This Metformin-mediated effect was conserved in vivo; Metformin-treatment significantly reduced levels of KIC in the muscle (by 69%) and serum (by 56%) isolated from iMSUD mice, and restored levels of mitochondrial metabolites (e.g. AMP and other TCA). The drug also decreased the expression of mitochondrial branched chain amino transferase (BCAT) which produces KIC in skeletal muscle. This suggests that Metformin can restore skeletal muscle homeostasis in MSUD by decreasing mitochondrial KIC production.
Article
Full-text available
Background Metadichol (1,2) is a Nano emulsion of long-chain alcohols called policosanols which are found in many foods like rice, wheat, grapes, sugar cane, apple and many others (3). It acts on membrane receptors in cells throughout the body to stimulate the immune system and inhibit a variety of disease processes, including those that result in metabolic diseases such as diabetes, obesity and hypertension. Methods A 38-year-old male of middle eastern origin was diagnosed as diabetic after complaining of tiredness and bouts of hunger. He was not on any medication and chose to be treated with Metadichol @ 10 mg per day. Findings Metadichol helped to lower his fasting blood sugar level from 300 mg/dl to normal in 6 weeks. His HBA1C was reduced from 9.8% to 6.2% in 12 weeks. After 32 more months, his diabetic indicators remain normal. Interpretation Metadichol is safe and effective in controlling blood sugar and HbA1C levels in humans. Metadichol has been shown to bind to the vitamin D receptor (2) as an inverse agonist. However, it acts more like a protean agonist ligand (4) to increase or decrease activity depending on the system. Since Metadichol has no known negative side effects and consists of natural components of common foods, Metadichol has the potential to serve as a novel treatment for type 2 diabetes.
Article
Full-text available
In recent years, vitamin D has been received increased attention due to the resurgence of vitamin D deficiency and rickets in developed countries and the identification of extraskeletal effects of vitamin D, suggesting unexpected benefits of vitamin D in health and disease, beyond bone health. The possibility of extraskeletal effects of vitamin D was first noted with the discovery of the vitamin D receptor (VDR) in tissues and cells that are not involved in maintaining mineral homeostasis and bone health, including skin, placenta, pancreas, breast, prostate and colon cancer cells, and activated T cells. However, the biological significance of the expression of the VDR in different tissues is not fully understood, and the role of vitamin D in extraskeletal health has been a matter of debate. This report summarizes recent research on the roles for vitamin D in cancer, immunity and autoimmune diseases, cardiovascular and respiratory health, pregnancy, obesity, erythropoiesis, diabetes, muscle function, and aging.
Article
Obesity, type 2 diabetes mellitus and cardiovascular disease are at epidemic proportions in developed nations globally, representing major causes of ill-health and premature death. The search for drug targets to counter the growing prevalence of metabolic diseases has uncovered G-protein-coupled receptor 120 (GPR120). GPR120 agonism has been shown to improve inflammation and metabolic health on a systemic level via regulation of adiposity, gastrointestinal peptide secretion, taste preference and glucose homeostasis. Therefore, GPR120 agonists present as a novel therapeutic option that could be exploited for the treatment of impaired metabolic health. This review summarizes the current knowledge of GPR120 functionality and the potential applications of GPR120-specific agonists for the treatment of disease states such as obesity, type 2 diabetes mellitus and cardiovascular disease.
Article
Physical activity is recognised to be an efficient measure in improving glycemic control in the treatment of type 2 diabetes. This evidence is lacking in type I diabetes but type 1I diabetics benefit from the same advantages like the general population. For many type I diabetics, especially younger patients, sport represents an important modality in the treatment of their disease but also of their quality of life. However, this is often a challenge for the patient as well as for the physician regarding the metabolic consequences (hypo- but also hyperglycemia) which can appear in relation with physical activity. There are existing general recommendations concerning the intake of carbohydrates and the reduction of insulin doses but those have to be adapted individually for each patient and depend significantly on different sports and on the intensity of sport.
The effects of policosanol (50–500 mg/kg) administered orally for 24 months to Sprague Dawley rats of both sexes were investigated. No differences related to daily clinical observations, weight gain, food consumption, or mortality (survival analysis) between groups were found. Histopathological study showed that the frequency of the occurrence of non-neoplastic and neoplastic (benign and malignant) lesions was similar in the control and policosanol-treated groups. The lesions observed in this study were similar to the spontaneous lesions reported in this species in previous studies. Since no drug-related increase in the occurrence of malignant or benign neoplasms was found, nor acceleration in tumors growth in any specific group was observed, this study shows no evidence of policosanol induced carcinogenicity in this strain of rats. © 1994 Wiley-Liss, Inc.
Article
The superfamily of G protein-coupled receptors (GPCRs) includes at least 800 seven-transmembrane receptors that participate in diverse physiological and pathological functions. GPCRs are the most successful targets of modern medicine, and approximately 36% of marketed pharmaceuticals target human GPCRs. However, the endogenous ligands of more than 140 GPCRs remain unidentified, leaving the natural functions of those GPCRs in doubt. These are the so-called orphan GPCRs, a great source of drug targets. This review focuses on the signaling transduction pathways of the adhesion GPCR family, the LGR subfamily, and the PSGR subfamily, and their potential functions in immunology, development, and cancers. In this review, we present the current approaches and difficulties of orphan GPCR deorphanization and characterization.
Article
Omega-3 fatty acids (omega-3 FAs), DHA and EPA, exert anti-inflammatory effects, but the mechanisms are poorly understood. Here, we show that the G protein-coupled receptor 120 (GPR120) functions as an omega-3 FA receptor/sensor. Stimulation of GPR120 with omega-3 FAs or a chemical agonist causes broad anti-inflammatory effects in monocytic RAW 264.7 cells and in primary intraperitoneal macrophages. All of these effects are abrogated by GPR120 knockdown. Since chronic macrophage-mediated tissue inflammation is a key mechanism for insulin resistance in obesity, we fed obese WT and GPR120 knockout mice a high-fat diet with or without omega-3 FA supplementation. The omega-3 FA treatment inhibited inflammation and enhanced systemic insulin sensitivity in WT mice, but was without effect in GPR120 knockout mice. In conclusion, GPR120 is a functional omega-3 FA receptor/sensor and mediates potent insulin sensitizing and antidiabetic effects in vivo by repressing macrophage-induced tissue inflammation.